Assessment of diffusion-weighted MRI and 18F-fluoro-deoxyglucose PET/CT in monitoring early response to neoadjuvant chemotherapy in adenocarcinoma of the esophagogastric junction

Journal of Gastrointestinal and Liver Diseases

Volumn 22, Issue 1, 2013, Pages 45-52

  Weber, Marc André ^a   Bender, Karen ^a   von Gall, Carl Christian ^a,c   Stange, Annika ^b   Grünberg, Katharina ^a   Ott, Katja ^a   Haberkorn, Uwe ^a   Kauczor, Hans Ulrich ^a   Zechmann, Christian ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Adenocarcinoma; Apparent diffusion coefficient; Chemotherapy; Diffusion weighted imaging; Esophageal cancer; Esophagogastric junction; Magnetic resonance imaging; Overall survival; Positron emission tomography; Response assessment

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUORODEOXYGLUCOSE F 18; GADOBUTROL; IOPROMIDE; OXALIPLATIN; ANTINEOPLASTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; CANCER PROGNOSIS; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIFFUSION WEIGHTED IMAGING; DRUG RESPONSE; FEMALE; FOLLOW UP; GASTROINTESTINAL CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LOWER ESOPHAGUS SPHINCTER; MALE; METASTASIS; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; ADENOCARCINOMA; ADJUVANT THERAPY; AGED; CANCER STAGING; COMPARATIVE STUDY; DIAGNOSTIC USE; DRUG MONITORING; ESOPHAGEAL NEOPLASMS; ESOPHAGUS RESECTION; EVALUATION STUDY; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MIDDLE AGED; MULTIMODAL IMAGING; PATHOLOGY; PROCEDURES; PROGNOSIS; SCINTISCANNING; SECONDARY; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DIFFUSION MAGNETIC RESONANCE IMAGING; DRUG MONITORING; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; ESOPHAGOGASTRIC JUNCTION; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 84875425805     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J; Australasian Gastro-Intestinal Trials Group. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007; 8: 226-234.
2. Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009; 27: 5062-5067.
3. Sjoquist KM, Burmeister BH, Smithers BM, et al; Australasian GastroIntestinal Trials Group. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011; 12: 681-692.
4. van Hagen P, Hulshof MC, van Lanschot JJ, et al; CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366: 2074-2084.
5. Lowy AM, Rich TA, Skibber JM, Dubrow RA, Curley SA. Preoperative infusional chemoradiation, selective intraoperative radiation, and resection for locally advanced pelvic recurrence of colorectal adenocarcinoma. Ann Surg 1996; 223: 177-185.
6. Blank S, Stange A, Sisic L, et al. Preoperative therapy of esophagogastric cancer: the problem of nonresponding patients. Langenbecks Arch Surg 2013; 398: 211-220.
7. Lordick F, Ott K, Krause BJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 2007; 8: 797-805.
8. 18F])FDG-PET/CT. Acta Oncol 2012; 51: 636-644.
9. 18FDG-PET/CT. Ann Surg Oncol 2012; 19: 2178-2185.
10. Zum Büschenfelde CM, Herrmann K, Schuster T, et al. (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial. J Nucl Med 2011; 52: 1189-1196.
11. Zhu W, Xing L, Yue J, et al. Prognostic significance of SUV on PET/CT in patients with localized oesophagogastric junction cancer receiving neoadjuvant chemotherapy/chemoradiation: a systemic review and meta-analysis. Br J Radiol 2012; 85: e694-e701.
12. Hortling N, Layer G, Decker P. Oesophageal carcinoma: In: Layer, van Kaick, and Delorme's Radiological diagnostics in oncology. Springer, Heidelberg 2006: 1-16.
13. Hansmann J, Grenacher L. Radiological imaging of the upper gastrointestinal tract. Part I: The esophagus. Radiologe 2006; 46: 1077-1088.
14. Krupski-Berdien G. MRI of esophagus. N staging and more. Radiologe 2007; 47: 119-122.
15. Riddell AM, Allum WH, Thompson JN, Wotherspoon AC, Richardson C, Brown G. The appearances of oesophageal carcinoma demonstrated on high-resolution, T2-weighted MRI, with histopathological correlation. Eur Radiol 2007; 17: 391-399.
16. Chenevert TL, Stegman LD, Taylor JM, et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 2000; 92: 2029-2036.
17. Hosonuma T, Tozaki M, Ichiba N, et al. Clinical usefulness of diffusion-weighted imaging using low and high b-values to detect rectal cancer. Magn Reson Med Sci 2006; 5: 173-177.
18. Sasaki T, Shinya S, Nakagawa Y, et al. Diffusion-weighted imaging is a feasible method for screening colorectal cancer: report of a case. Hepatogastroenterology 2007; 54: 1951-1953.
19. Shinya S, Sasaki T, Nakagawa Y, Guiquing Z, Yamamoto F, Yamashita Y The usefulness of diffusion-weighted imaging (DWI) for the detection of gastric cancer. Hepatogastroenterology 2007; 54: 1378-1381.
20. Lorenzen S, von Gall C, Stange A, et al. Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial. BMC Cancer 2011; 11: 266.
21. Becker K, Mueller JD, Schulmacher C, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 2003; 98: 1521-1530.
22. Becker K, Reim D, Novotny A, et al. Proposal for a multifactorial prognostic score that accurately classifies 3 groups of gastric carcinoma patients with different outcomes after neoadjuvant chemotherapy and surgery. Ann Surg 2012; 256: 1002-1007.
23. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
24. Ba-Ssalamah A, Zacherl J, Noebauer-Huhmann IM, et al. Dedicated multi-detector CT of the esophagus: spectrum of diseases. Abdom Imaging 2009; 34: 3-18.
25. Padhani AR, Liu G, Koh DM, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009; 11: 102-125.
26. Shuto K, Saito H, Ohira G, et al. Diffusion-weighted MR imaging for postoperative nodal recurrence of esophageal squamous cell cancer in comparison with FDG-PET. Gan To Kagaku Ryoho 2009; 36: 2468-2470.
27. Thoeny HC, De Keyzer F, Chen F, et al. Diffusion-weighted magnetic resonance imaging allows noninvasive in vivo monitoring of the effects of combretastatin a-4 phosphate after repeated administration. Neoplasia 2005; 7: 779-787.
28. Lerut T, Flamen P, Ectors N, et al. Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction: A prospective study based on primary surgery with extensive lymphadenectomy Ann Surg 2000; 232: 743-752.
29. Cordin J, Lehmann K, Schneider PM. Clinical staging of adenocarcinoma of the esophagogastric junction. Recent Results Cancer Res 2010; 182: 73-83.